Which targeted drug (bevacizumab, ramucirumab, aflibercept, or anti-EGFR?) is better for RAS-wt patients in 2nd line treatment after bevacizumab therapy?
Which targeted drug (bevacizumab, ramucirumab, aflibercept, or anti-EGFR?) is better for RAS-wt patients in 2nd line treatment after bevacizumab therapy?
Assoc. Prof. Joleen Hubbard, Assoc. Prof. Yu Sunakawa
Ass. Prof. Joleen Hubbard and Ass. Prof. Yu Sunakawa discuss the Clinical Question: Which targeted drug is better for RAS-wt patients in 2nd line treatment after bevacizumab therapy?
Assoc. Prof. Joleen Hubbard
Medical Oncologist
Allina Health Cancer Institute
United States (US)
Assoc. Prof. Yu Sunakawa
Medical Oncologist
St Marianna University
Japan
| 
5 min
|
2017
download resources
This programme was made for you: your opinion matters
Share your feedback in just 4 clicks and help us to continue to create the content you need.
I agree that this educational programme:
GI CONNECT is an initiative of COR2ED, supported by an Independent Educational Grant from Bayer.
Other programmes of interest
27 min
Other programmes developed by Assoc. Prof. Joleen Hubbard
Assoc. Prof. Joleen Hubbard
Medical Oncologist
Allina Health Cancer Institute
United States (US)
Other programmes developed by Assoc. Prof. Yu Sunakawa
Assoc. Prof. Yu Sunakawa
Medical Oncologist
St Marianna University
Japan
